In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

Mutation-Agnostic Treatment Advances

 
• By Sushmita Panda
  
Cancer Cells
Aptose reports promising results for triplet therapy for mutation-agnostic frontline AML. (Shutterstock)

More from Clinical Trials

More from Therapy Areas